AgeX Therapeutics, Inc.
About AgeX Therapeutics, Inc.
The mission of AgeX is to apply technology related to pluripotent stem cells and telomere biology to aging and age-related disease. AgeX is expected to have three initial areas of focus: 1) the development of pluripotent stem cell-derived brown adipocytes for the treatment of Type II diabetes and potentially obesity; 2) the development of vascular progenitors to improve circulation to ischemic tissues in patients suffering from heart disease; and 3) Induced Tissue Regeneration (iTR)TM - an emerging technology invented and patented by BioTime scientists that is designed to profoundly reprogram aged tissues in the body in a way that can restore a regenerative phenotype normally expressed only in the first few weeks of human development.94 articles about AgeX Therapeutics, Inc.
-
AgeX Therapeutics Reports Third Quarter 2023 Financial Results
11/14/2023
AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter and nine months ended September 30, 2023.
-
Serina Therapeutics and AgeX Therapeutics Enter into Merger Agreement
8/30/2023
Serina Therapeutics, Inc., a privately-held, clinical-stage biotechnology company developing a pipeline of therapies for the treatment of Parkinson’s Disease and other neurological diseases, entered into a merger agreement with AgeX Therapeutics, Inc. on August 29, 2023, under which Serina will merge with a wholly-owned subsidiary of AgeX in an all-stock transaction.
-
AgeX Therapeutics Reports Second Quarter 2023 Financial Results
8/14/2023
AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter and six months ended June 30, 2023.
-
AgeX Therapeutics Closes $36,000,000 Debt Exchange for Preferred Stock
7/24/2023
AgeX Therapeutics, Inc. reported that on July 24, 2023, AgeX issued to Juvenescence Limited 211,600 shares of a newly authorized Series A Preferred Stock and 148,400 shares of a newly authorized Series B Preferred Stock in exchange for the cancellation of a total of $36 Million of indebtedness consisting of the outstanding principal amount of certain loans made by Juvenescence to AgeX and loan origination fees accrued with respect to those loans.
-
AgeX Therapeutics Announces $36,000,000 Debt Exchange for Preferred Stock
7/21/2023
AgeX and Juvenescence entered into an Exchange Agreement pursuant to which AgeX agreed to issue to Juvenescence 211,600 shares of a newly authorized Series A Preferred Stock and 148,400 shares of a newly authorized Series B Preferred Stock in exchange for the cancellation of a total of $36 Million of indebtedness consisting of the outstanding principal amount of certain loans made by Juvenescence to AgeX and loan origination fees accrued with respect to those loans.
-
AgeX Therapeutics Announces Appeal of NYSE American Determination
5/23/2023
AgeX Therapeutics, Inc. announced that on May 17, 2023 it received a notice from the staff of the NYSE American indicating that they intend to commence proceedings to delist AgeX common stock from the Exchange based upon AgeX’s non-compliance with the stockholders’ equity requirements set forth in Sections 1003, and of the Exchange’s Company Guide by the end of a compliance plan period that expired on May 17, 2023.
-
AgeX Therapeutics Reports First Quarter 2023 Financial Results
5/12/2023
AgeX Therapeutics, Inc., a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for quarter ended March 31, 2023.
-
AgeX Therapeutics Reports Fourth Quarter and Annual 2022 Financial Results
3/31/2023
AgeX Therapeutics, Inc., a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for fourth quarter and the full year ended December 31, 2022.
-
AgeX Therapeutics Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements
11/25/2022
AgeX Therapeutics, Inc. announced that on November 22, 2022 it received notification from the staff of the NYSE American that the Exchange has accepted a revised listing compliance plan from AgeX and has granted AgeX an extension of time to regain compliance with the Exchange’s continued listing standards as set forth in Section 1003 and of the Exchange Company Guide by increasing its stockholders equity to not less than $4,000,000.
-
AgeX Therapeutics Reports Third Quarter 2022 Financial Results
11/10/2022
AgeX Therapeutics, Inc. reported its financial and operating results for the quarter ended September 30, 2022.
-
AgeX Therapeutics Reports Second Quarter 2022 Financial Results
8/12/2022
AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter ended June 30, 2022.
-
Dr. Joanne Hackett Appointed Chairperson of AgeX Board of Directors
5/18/2022
AgeX Therapeutics, Inc., a biotechnology company developing therapeutics for human aging and regeneration, announced that Dr. Joanne Hackett has been appointed Chairperson of AgeX’s Board of Directors.
-
AgeX Therapeutics Reports First Quarter 2022 Financial Results
5/13/2022
AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter ended March 31, 2022.
-
AgeX Therapeutics Reports Fourth Quarter and Annual 2021 Financial Results
3/29/2022
AgeX Therapeutics, Inc., a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for fourth quarter and the full year ended December 31, 2021.
-
AgeX Therapeutics to Collaborate With University of California, Irvine, on Research Program for Exosome-Based Therapies for Certain Brain Disorders
12/14/2021
AgeX Therapeutics , Inc. announced today a research collaboration with the University of California, Irvine (UCI).
-
AgeX Therapeutics’ Licensee ImStem Biotechnology Announces First U.S. Multiple Sclerosis Patient Dosed with IMS001
11/30/2021
AgeX Therapeutics, Inc. announced today that ImStem Biotechnology, Inc. (“ImStem”), a biopharmaceutical company developing human embryonic stem cell (ESC)-derived mesenchymal stem cells, has dosed the first U.S. multiple sclerosis (MS) patient with ImStem’s lead investigational drug candidate IMS001 at the Shepherd Center in Atlanta, GA.
-
AgeX Therapeutics Reports Third Quarter 2021 Financial Results
11/12/2021
AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter ended September 30, 2021.
-
AgeX Therapeutics Reports Second Quarter 2021 Financial Results
8/13/2021
AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter ended June 30, 2021.
-
AgeX Therapeutics and LyGenesis Terminate Merger Negotiations
7/23/2021
AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and cell regeneration, and LyGenesis, Inc. (“LyGenesis”), a privately held biotechnology company developing cell therapies that enable organ regeneration, announced today that they have discontinued negotiations for a merger agreement.
-
AgeX Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update
5/17/2021
AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter ended March 31, 2021.